Technology | June 16, 2009

Discovery PET/CT 690 for Exploration

Discovery PET/CT 600

As Discovery PET/CT 600 series continues to expand, GE Healthcare introduced the Discovery PET/CT 690 – a molecular imaging tool designed go beyond the needs of the clinical practice and provide the necessary tools and technologies to explore the future of PET/CT imaging.

The Discovery PET/CT 690 was built with the academic in mind. The breakthrough scanner allows for improved quantitative accuracy and the reconstruction power needed to explore the potential of PET/CT imaging. The new system leverages the high-speed, high-resolution capabilities of GE’s LightSpeed VCT. Combining the innovative molecular imaging platform with GE’s advanced volume CT and Discovery Dimension console technologies, the Discovery PET/CT 690 provides users with answers to flexibility, time, accuracy and motion.

With a unique detector configuration designed for sensitivity and efficiency, researchers and clinicians have the necessary speed in workflow and protocol flexibility to help explore new frontiers in clinical techniques, drug discovery and motion management.

The Discovery PET/CT 690 includes the exclusive IBM BladeCenter, where users have the ability to reconstruct PET images in minutes instead of hours, potentially improving workflow of detailed studies.

GE’s breakthrough VUE Point FX, the next generation in high-definition reconstruction, provides state of the art performance and unique timing resolution stability.

Like all of the Discovery PET/CT 600 Series products, he 690 incorporates MotionFree imaging technologies into the clinical workflow. This technology has the potential to improve small lesion detection and image quality when coupled with MotionFree techniques, especially in areas affected by patient motion. Leveraging the coincidence timing capabilities of the Discovery PET/CT 690, VUE Point FX incorporates time-of-flight acquisitions into the VUE Point HD 3D iterative process, providing for image quality improvements in PET/CT scan modes.

With the Discovery PET/CT 690, imagers can take advantage of advanced reconstruction and motion techniques at a routine pace. GE's next generation of MotionFree imaging technologies on the new Discovery PET/CT 690 are designed to give clinicians detailed images even in areas of the body subject to movement caused by respiration and cardiac movement. The scanner’s techniques address motion challenges including artifacts, blurring and quantification. With the MotionFree suite components, Motion Match to align the PET and CT gated studies, and Motion VUE to improve the reading of motion studies, motion management can be incorporated in research protocols. Users now have the ability to further diagnose and stage with accuracy, plan with precision and monitor with confidence.

With specialized detector configuration designed for sensitivity, event throughput and efficiency, researchers and clinicians have the necessary speed in workflow, protocol flexibility and unique timing resolution technology to help forge new frontiers in clinical techniques, drug discovery and motion management.

The Discover PET/CT 690 was released in 2009.

For more information: www.gehealthcare.com

Related Content

Siemens Healthineers Announces FDA Clearance of syngo.via VB30 Molecular Imaging Software
Technology | Nuclear Imaging | July 16, 2018
At the 2018 Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI), June 23-26 in Philadelphia...
Philips North America and GE Healthcare Win IMV PET Imaging ServiceTrak Awards
News | PET Imaging | June 25, 2018
IMV, part of the Science and Medicine Group and a market research and business intelligence provider to the imaging...
FDA Clears New Imaging Functionalities for Biograph mCT PET/CT Systems
Technology | PET-CT | June 21, 2018
Siemens Healthineers will announce U.S. Food and Drug Administration (FDA) clearance of four new system features for...
PET/CT Changes Care for 59 Percent of Suspected Recurrent Prostate Cancer Cases
News | Prostate Cancer | June 13, 2018
A recently presented investigational clinical trial evaluated the impact of 18F fluciclovine positron emission...
Nuclear imaging scan showing very good tissue delineation. Scan performed on a Biograph Vision positron emission tomography/computed tomography (PET-CT) system from Siemens Healthineers.

Nuclear imaging scan showing very good tissue delineation. It offers crisp overall image quality and sharply delineates the muscle and fat planes, vertebral margins and end plates, billiary radicals, renal calyces, aortic wall and papillary muscles of the heart. Scan performed on a Biograph Vision positron emission tomography/computed tomography (PET-CT) system from Siemens Healthineers.

Technology | PET-CT | June 05, 2018
June 5, 2018 — The U.S.
News | Computed Tomography (CT) | May 21, 2018
The Istituto Oncologico Veneto (IOV) in Padua, Italy, has acquired MILabs’ latest-generation Versatile Emission...
News | Radiopharmaceuticals and Tracers | May 09, 2018
Blue Earth Diagnostics signed an exclusive, worldwide agreement with Scintomics GmbH, Germany, a specialist in...
In scans of a 62-yr-old man with Gleason 4+3 PCa treated with radical prostatectomy, with rising PSA level (1.32) and PSA doubling time of 3.7 months, 64CuCl2-PET/CT images revealed 2 positive small left iliac lymph nodes (A,C), whereas 18F-Choline PET/CT (B,D) was negative (arrows).

In scans of a 62-yr-old man with Gleason 4+3 PCa treated with radical prostatectomy, with rising PSA level (1.32) and PSA doubling time of 3.7 months, 64CuCl2-PET/CT images revealed 2 positive small left iliac lymph nodes (A,C), whereas 18F-Choline PET/CT (B,D) was negative (arrows). Image courtesy of A Piccardo et al., Galliera Hospital, Genoa, Italy.

News | Prostate Cancer | March 07, 2018
An Italian study featured in the March i
Axumin PET Agent Added to NCCN Guidelines for Suspected Recurrent Prostate Cancer
News | PET Imaging | February 21, 2018
Blue Earth Diagnostics announced that Axumin (fluciclovine F 18) injection has been added to the National Comprehensive...
PSMA PET-CT Clearly Differentiates Prostate Cancer from Benign Tissue

68Ga-PSMA PET/CT images showing multifocal PCA in peripheral zone with GS of 5 1 5 5 10. (A and C) Axial PET images. (B and D) Fused PET/CT images. SUVmax of lesion in B was 84.3 and that of lesion in D was 5.7. IRS was 3, and 80% of cells were stained. Credit: Senior author V Prasad, Charité Universitätsmedizin Berlin, Berlin, Germany.

News | PET-CT | February 05, 2018
February 5, 2018 — Using nuclear medicine...
Overlay Init